Gene expression profiling identified TP53(Mut)PIK3CA(Wild) as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors

Triple-negative breast cancer (TNBC) accounts for 15–30% of all breast cancer cases and is clinically difficult to treat due to the lack of hormone or human epidermal growth factor receptor 2 receptors, which are usually targeted by the most successful therapeutic approaches. Immune checkpoint inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Jia'Nan, Ding, Xiaofang, Xu, Shouxia, Zhu, Bo, Jia, Qingzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068237/
https://www.ncbi.nlm.nih.gov/pubmed/32218835
http://dx.doi.org/10.3892/ol.2020.11381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068237/
https://www.ncbi.nlm.nih.gov/pubmed/32218835
http://dx.doi.org/10.3892/ol.2020.11381

Ejemplares similares